Tempus AI Exceeds Q2 Estimates, Raises Full-Year Revenue Guidance to $1.26 Billion

Tempus AI reported a Q2 adjusted loss of 22 cents per share, beating analyst estimates. Revenue was $314.64 million, up 89.6% YoY, driven by growth in genomics, oncology testing, and data and services. The company's database now stands at over 350 petabytes of connected clinical and molecular data. Tempus AI increased its guidance, expecting full-year 2025 revenue of approximately $1.26 billion, representing 82% annual growth.

Tempus AI Inc. (NASDAQ: TEM) reported its second-quarter financial results, showcasing robust growth and improved financial performance. The AI-focused precision medicine and patient care company reported an adjusted loss of 22 cents per share, which exceeded analyst estimates of 24 cents per share. Revenue for the quarter reached $314.64 million, marking an 89.6% year-over-year increase, surpassing consensus estimates of $296.85 million [1].

The company's growth was driven by significant increases in genomics, oncology testing, and data and services. Genomics revenue surged by 115.3% year-over-year to $241.8 million, while oncology testing revenue grew by 32.9% to $133.2 million. Hereditary testing sales, through Ambry Genetics, reached $97.3 million, up 33.6% year-over-year. Revenue from Data and services totaled $72.8 million, delivering a 35.7% year-over-year growth, led by Insights (data licensing), which grew 40.7% year-over-year [2].

Tempus AI's database now stands at over 350 petabytes of connected clinical and molecular data, reflecting the company's extensive integration efforts. The company reported a quarterly gross profit of $195.0 million, representing a 158.3% year-over-year increase. Adjusted EBITDA improved to ($5.6 million) in the second quarter of 2025, compared to ($31.2 million) in the second quarter of 2024, marking a $25.6 million year-over-year improvement [2].

Tempus AI increased its full-year 2025 revenue guidance to approximately $1.26 billion, representing an 82% annual growth, compared to the previous estimate of between $1.24 billion and $1.25 billion. The company also reaffirmed its full-year 2025 adjusted EBITDA guidance of $5 million, an improvement of approximately $110 million over 2024. The company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ejection fraction software in July [1].

Tempus AI shares were up 5.79% after hours, trading at $55.21 at the time of publication on Tuesday, August 6, 2025 [1].

References:
[1] https://finance.yahoo.com/news/tempus-ai-raises-outlook-ceo-111348147.html
[2] https://www.stocktitan.net/news/TEM/tempus-reports-second-quarter-2025-9mftg8oo8qee.html